Innovative clinical diagnostics
Novacyt (PA:ALNOV) is a high growth diagnostics company that has developed innovative technology platforms specifically in liquid-based cytology (LBC) testing and new-generation molecular products based on real-time quantitative polymerase chain reaction (qPCR). Novacyt also has an established manufacturing and global distribution channel, which offers a wide range of profitable infectious disease diagnostic products. 2017 could be a transformative year, as the integration of recent acquisitions helps accelerate sales momentum of its key products NOVAprep (LBC) and Primerdesign’s genesig (qPCR). By targeting wider markets the company aims to achieve EBITDA break-even in 2017.
Organic growth, M&A and R&D
Novacyt, listed on Alternext, is a group of companies that offer novel clinical diagnostics platforms, but also conventional laboratory products. The two most notable recent transactions were the merger of Novacyt with Lab21 in June 2014 and the acquisition of Primerdesign in May 2016. Novacyt’s operations are split into three business segments: cytology – a core business involving innovative LBC diagnostic equipment NOVAprep and consumables; molecular testing – Primerdesign, innovative real-time qPCR equipment and consumables; and diagnostics – laboratory products (Lab21 and its subsidiaries). Novacyt’s strategy has three pillars: commercial expansion of the existing product portfolio, progressing the R&D pipeline to bring innovative products to the market and opportunistic acquisitions of synergistic businesses.
To read the entire report Please click on the pdf File Below